Neu Health, a London-based HealthTech startup spun out of the University of Oxford, has secured €1.9 million in funding from Oxford Science Enterprises (OSE) and Cedars-Sinai Intellectual Property Company.
Caroline Cake, CEO of Neu Health, shared: “Our goal is to change what’s possible in neurology care. Our partnership with Cedars-Sinai and OSE shows the growing global commitment to improving care for Parkinson’s disease and dementia. Together, we’re building a future where technology helps patients, care givers and doctors manage these challenging conditions.”
Founded in 2022 by Caroline Cake and Dr Kinan Muhammed, this investment marks a significant step in the company’s growth as it expands beyond the UK and prepares for entry into the US market. Neu Health has developed a digital, smartphone-based neurology care platform aimed at improving clinical outcomes for patients with Parkinson’s disease and dementia by offering a more data-driven, personalised approach to neurological care.
Backed by over a decade of research and clinical validation from experts at the University of Oxford, the Neu Health platform combines AI-driven data analytics with real-world patient interactions to provide clinicians with actionable insights.
The system links a patient app with a care team dashboard, translating motor and non-motor symptoms, cognitive function, and mental health indicators into objective, trackable metrics.
Dr John Glaser, Chairman of the Board at Neu Health, said: “Neurological disease has claimed my father and my brother. The Neu Health technology will enable clinicians, patients and family caregivers to take major steps forward in managing these diseases. I am delighted to see the resources and talents of Cedars-Sinai, Oxford Science Enterprises and Neu Health brought to bear to materially advance the management of the health and healthcare of families like mine.”
The latest funding follows Neu Health’s participation in Cedars-Sinai’s 10th Accelerator program, a key milestone that connected the startup with one of the leading healthcare institutions in the US.
Now, as part of its expansion, Neu Health will pilot its digital neurology platform at Cedars-Sinai, with the first 150 patients set to begin using the app in a six-month trial. This will provide the company with valuable clinical data and insights as it refines its approach for the US healthcare market.
“The research produced at Oxford is of the highest calibre,” said Shlomo Melmed, MB, ChB, executive vice president of Medicine and Health Sciences and dean of the Medical Faculty at Cedars-Sinai. “An ongoing relationship with Oxford Science Enterprises will serve our patients and also strengthen the academic and clinical missions of Cedars-Sinai.”\
The investment in Neu Health is the first under a newly established partnership between Oxford Science Enterprises and Cedars-Sinai Intellectual Property Company, aimed at co-building and co-investing in Oxford-founded health-tech startups. This collaboration is designed to accelerate the US market entry of early-stage companies, providing them with essential commercial and clinical insights while enabling real-world testing of their healthcare technologies.
Heather Roxborough, PhD, senior partner of Health Tech at Oxford Science Enterprises, highlighted the strategic importance of this investment, saying, “We are excited to strengthen our relationship with Cedars-Sinai, a leading US health system, given our shared commitment to commercialising world-leading research and building innovative businesses. This partnership plays a critical role in accelerating US market entry for our companies by providing access to invaluable commercial and clinical insights and the opportunity to test our healthcare technologies live in the US market.”
As Neu Health looks ahead to scaling its platform, this funding and its pilot programme at Cedars-Sinai mark a major step toward establishing itself as a notable player in digital neurology care.
